ConductScience.org, home

Library / Genes

TEK: TEK receptor tyrosine kinase

1 protein, 88 patents, 8 drugs, 362 trials, 5,155 NIH grants and 9,371 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolTEKHGNC
NameTEK receptor tyrosine kinaseHGNC
NCBI Gene ID7010NCBI Gene
HGNC IDHGNC:11724HGNC
EnsemblENSG00000120156NCBI Gene
AliasesCD202B, CD202b, GLC3E, TIE-2, TIE2, VMCM, VMCM1NCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
Q02763Angiopoietin-1 receptor1,12417Ensembl, GeneID, HGNCUniProt

Patents 88

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
WO 2026156288 A12026-07-2323Q02763Espacenet
EP 4650780 A22025-11-1910256Q02763Espacenet
EP 4641201 A22025-10-2910567Q02763Espacenet
JP 2025147176 A2025-10-0613098Q02763Espacenet
JP 2025529142 A2025-09-044638Q02763Espacenet
JP 2025529142 A2025-09-047858Q02763Espacenet
KR 1020250130525 A2025-09-0241Q02763Espacenet
EP 4591878 A22025-07-301Q02763Espacenet
US 12371689 B22025-07-294638Q02763Espacenet
US 12371689 B22025-07-297858Q02763Espacenet

Drugs 8

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
ALTIRATINIBCHEMBL3545365Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL
CE-245677CHEMBL3910075Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL
CEP-11981CHEMBL2010872Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL
FORETINIBCHEMBL1230609Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL
GLESATINIBCHEMBL3989914Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL
PEXMETINIBCHEMBL3991932Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL
REGORAFENIBCHEMBL1946170Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL
VANDETANIBCHEMBL24828Tyrosine-protein kinase TIE-2 inhibitorINHIBITORChEMBL

Trials 362

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07559864REGORAFENIBPHASE2ClinicalTrials.gov
NCT07537985REGORAFENIBClinicalTrials.gov
NCT07514455REGORAFENIBPHASE2ClinicalTrials.gov
NCT07514429REGORAFENIBPHASE2ClinicalTrials.gov
NCT07501351REGORAFENIBPHASE2ClinicalTrials.gov
NCT07495579REGORAFENIBPHASE2ClinicalTrials.gov
NCT07463248REGORAFENIBPHASE2ClinicalTrials.gov
NCT07379047REGORAFENIBPHASE2/PHASE3ClinicalTrials.gov
NCT07343791REGORAFENIBEARLY_PHASE1ClinicalTrials.gov
NCT07328009REGORAFENIBPHASE2ClinicalTrials.gov

NIH grants 5155

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant662,025NIH's project files
P30CA008748Cancer Center Support Grant442,025NIH's project files
P30CA060553The Robert H. Lurie Comprehensive Cancer Center192,025NIH's project files
ZIAES025034Characterization And Functional Significance Of P450 Arachidonate Epoxygenases132,025NIH's project files
P30CA006973Regional Oncology Research Center122,025NIH's project files
UL1TR001863Yale Clinical and Translational Science Award122,025NIH's project files
P30CA013330Cancer Center Support Grant102,025NIH's project files
P30EY014104P30 Core Grant for Vision Research92,025NIH's project files
P50CA127001SPORE in Brain Cancer92,025NIH's project files
R01HL117952Venous Malformations (VM): A Murine Mdoel to Identify Therapies to Target Aberrant Venous Development92,025NIH's project files

Papers 9371

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42818173PubTator, text miningPubMed
42817178PubTator, text miningPubMed
42814223PubTator, text miningPubMed
42796720PubTator, text miningPubMed
42783035PubTator, text miningPubMed
42780753PubTator, text miningPubMed
42762961PubTator, text miningPubMed
42758422PubTator, text miningPubMed
42733001PubTator, text miningPubMed
42732598PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license